Eli Lilly and Company (NYSE:LLY) Stake Lessened by Hyman Charles D

Hyman Charles D cut its stake in Eli Lilly and Company (NYSE:LLY) by 0.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,403 shares of the company’s stock after selling 20 shares during the period. Hyman Charles D’s holdings in Eli Lilly and Company were worth $8,979,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in LLY. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Morgan Stanley lifted its stake in Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares during the last quarter. Northern Trust Corp lifted its position in shares of Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,560,553 shares of the company’s stock valued at $2,658,438,000 after acquiring an additional 125,242 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on LLY. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Citigroup increased their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial increased their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, BMO Capital Markets raised their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $2.77 during trading hours on Wednesday, hitting $775.00. 2,010,705 shares of the company’s stock were exchanged, compared to its average volume of 3,076,480. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a market capitalization of $736.56 billion, a price-to-earnings ratio of 114.14, a PEG ratio of 1.45 and a beta of 0.37. The company’s 50-day moving average price is $761.22 and its 200-day moving average price is $674.88.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the firm earned $1.62 EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. On average, sell-side analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.